Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.
Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.
Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
The immediate precursor to NAD+ in the salvage pathway: NMNAT enzymes convert it to NAD+ in a single step. Whether NMN enters cells intact is genuinely disputed — a dedicated transporter (Slc12a8) has been reported, but the prevailing view is that most NMN is dephosphorylated to nicotinamide riboside at the cell surface, taken up, and re-phosphorylated. The distinction matters commercially far more than it does biologically.
Human trials consistently show NMN raises blood NAD+ levels. Effects on outcomes that matter — insulin sensitivity, muscle function, ageing markers — have been modest, inconsistent, and typically from small studies. The gap between the biomarker and the benefit is the whole story of this field.
Not an FDA-approved drug. Its supplement status is genuinely unsettled: FDA has concluded NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug and substantial clinical investigations were instituted and made public. That position is contested by industry and litigation has followed.
Well tolerated in trials up to the doses studied, over relatively short durations. Long-term human data do not exist. The same theoretical oncological consideration applies as for NAD+.
Human trials commonly used 250–900 mg once daily, oral. These reliably raise blood NAD+ (a biomarker) while showing inconsistent, generally modest effects on clinical outcomes.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.